PTA末梢DCBカテーテル市場：パイプラインレポート（開発段階、セグメント、地域・国、規制経路、主要企業）、2024年最新版

PTA末梢DCBカテーテルは、末梢動脈の再狭窄、つまり再狭窄を予防することを目的とした薬剤コーティング経皮経管血管形成術（PTA）バルーンです。PTA末梢DCBカテーテルは、血管の解剖学的構造を維持し、血管の治癒を促進し、長期の二重抗血小板療法の必要性を減少させながら、血管壁への迅速、短期間、均質、局所的な薬物送達を提供します。ステント内再狭窄（ISR）、分岐部、細い血管、長い病変の治療に使用できます。

当レポートでは、PTA末梢DCBカテーテル市場について調査し、製品概要と開発中のパイプライン製品動向、様々な開発段階にある製品の比較分析や進行中の臨床試験に関する情報、参入企業の最近の動向などを提供しています。

目次

第1章 目次

第2章 イントロダクション

• PTA末梢DCBカテーテルの概要

第3章 開発中の製品

• PTA末梢DCBカテーテル - 開発段階別パイプライン製品
• PTA末梢DCBカテーテル - 地域別パイプライン製品
• PTA末梢DCBカテーテル - 規制経路別パイプライン製品
• PTA末梢DCBカテーテル - 推定承認日別パイプライン製品
• PTA末梢DCBカテーテル - 進行中の臨床試験

第4章 PTA末梢DCBカテーテル- 各社開発中のパイプライン製品

• PTA末梢DCBカテーテル企業- 開発段階別のパイプライン製品
• PTA末梢DCBカテーテル- 開発段階別のパイプライン製品

第5章 PTA末梢DCBカテーテルの企業と製品の概要

• Acotec Scientific Co Ltd
• AnGes Inc
• AngioCure, Inc.
• Ascenion GmbH
• Becton Dickinson and Co
• Boston Scientific Corp
• Cardionovum GmbH
• Chansu Vascular Technologies LLC
• Concept Medical Inc
• Contego Medical LLC
• Cordis US Corp
• Dingke Medical Technology (Suzhou) Co Ltd
• eucatech AG
• Lifetech Scientific (Shenzhen) Co Ltd
• Lutonix Inc
• Medtronic Plc
• Micell Technologies Inc
• OrbusNeich
• Orchestra BioMed Inc
• Pulsus Medical LLC
• QualiMed Innovative Medizinprodukte GmbH
• Shanghai Easy-Flow Medical Tech Co Ltd
• Shenzhen Salubris Pharmaceuticals Co Ltd
• SiL Vascular Ltd
• Spectranetics Corp
• Stemplant LLC
• SurModics Inc
• Tailored Medical Devices Inc
• TransMed7 LLC
• Vascular Nanotransfer Technologies
• Zhejiang Batai Medical Technology Co Ltd
• Zylox-Tonbridge Medical Technology Co Ltd

第6章 PTA末梢DCBカテーテル- 最近の開発

第7章 付録

• 調査手法
• GlobalDataについて
• お問い合わせ
• 免責事項

List of Tables

• PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development
• PTA Peripheral DCB Catheters - Pipeline Products by Territory
• PTA Peripheral DCB Catheters - Pipeline Products by Regulatory Path
• PTA Peripheral DCB Catheters - Pipeline Products by Estimated Approval Date
• PTA Peripheral DCB Catheters - Ongoing Clinical Trials
• PTA Peripheral DCB Catheters Companies - Pipeline Products by Stage of Development
• PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development
• Glossary

List of Figures

• PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development
• PTA Peripheral DCB Catheters - Pipeline Products by Territory
• PTA Peripheral DCB Catheters - Pipeline Products by Regulatory Path
• PTA Peripheral DCB Catheters - Pipeline Products by Estimated Approval Date
• PTA Peripheral DCB Catheters - Ongoing Clinical Trials

GlobalData's Medical Devices sector report, "PTA Peripheral DCB Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the PTA Peripheral DCB Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis, or restenosis of the peripheral arteries. PTA Peripheral DCB catheters provide fast, short-term, homogenous, local drug delivery to the vessel wall, while preserving the anatomy of the vessel, promoting enhanced vessel healing, and reducing the need for prolonged dual antiplatelet therapy. They can be used to treat native and in-stent restenosis (ISR), bifurcations, small vessels, and long lesions.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the PTA Peripheral DCB Catheters under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of PTA Peripheral DCB Catheters and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of PTA Peripheral DCB Catheters under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 PTA Peripheral DCB Catheters Overview

3 Products under Development

• 3.1 PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development
• 3.2 PTA Peripheral DCB Catheters - Pipeline Products by Territory
• 3.3 PTA Peripheral DCB Catheters - Pipeline Products by Regulatory Path
• 3.4 PTA Peripheral DCB Catheters - Pipeline Products by Estimated Approval Date
• 3.5 PTA Peripheral DCB Catheters - Ongoing Clinical Trials

4 PTA Peripheral DCB Catheters - Pipeline Products under Development by Companies

• 4.1 PTA Peripheral DCB Catheters Companies - Pipeline Products by Stage of Development
• 4.2 PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development

5 PTA Peripheral DCB Catheters Companies and Product Overview

• 5.1 Acotec Scientific Co Ltd Company Overview
  • 5.1.1 Acotec Scientific Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 AnGes Inc Company Overview
  • 5.2.1 AnGes Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.3 AngioCure, Inc. Company Overview
  • 5.3.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview
• 5.4 Ascenion GmbH Company Overview
  • 5.4.1 Ascenion GmbH Pipeline Products & Ongoing Clinical Trials Overview
• 5.5 Becton Dickinson and Co Company Overview
  • 5.5.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
• 5.6 Boston Scientific Corp Company Overview
  • 5.6.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
• 5.7 Cardionovum GmbH Company Overview
  • 5.7.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
• 5.8 Chansu Vascular Technologies LLC Company Overview
  • 5.8.1 Chansu Vascular Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.9 Concept Medical Inc Company Overview
  • 5.9.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.10 Contego Medical LLC Company Overview
  • 5.10.1 Contego Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.11 Cordis US Corp Company Overview
  • 5.11.1 Cordis US Corp Pipeline Products & Ongoing Clinical Trials Overview
• 5.12 Dingke Medical Technology (Suzhou) Co Ltd Company Overview
  • 5.12.1 Dingke Medical Technology (Suzhou) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.13 eucatech AG Company Overview
  • 5.13.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview
• 5.14 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
  • 5.14.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.15 Lutonix Inc Company Overview
  • 5.15.1 Lutonix Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.16 Medtronic Plc Company Overview
  • 5.16.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
• 5.17 Micell Technologies Inc Company Overview
  • 5.17.1 Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.18 OrbusNeich Company Overview
  • 5.18.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
• 5.19 Orchestra BioMed Inc Company Overview
  • 5.19.1 Orchestra BioMed Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.20 Pulsus Medical LLC (Inactive) Company Overview
  • 5.20.1 Pulsus Medical LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
• 5.21 QualiMed Innovative Medizinprodukte GmbH Company Overview
  • 5.21.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
• 5.22 Shanghai Easy-Flow Medical Tech Co Ltd Company Overview
  • 5.22.1 Shanghai Easy-Flow Medical Tech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.23 Shenzhen Salubris Pharmaceuticals Co Ltd Company Overview
  • 5.23.1 Shenzhen Salubris Pharmaceuticals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.24 SiL Vascular Ltd Company Overview
  • 5.24.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.25 Spectranetics Corp Company Overview
  • 5.25.1 Spectranetics Corp Pipeline Products & Ongoing Clinical Trials Overview
• 5.26 Stemplant LLC Company Overview
  • 5.26.1 Stemplant LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.27 SurModics Inc Company Overview
  • 5.27.1 SurModics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.28 Tailored Medical Devices Inc Company Overview
  • 5.28.1 Tailored Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.29 TransMed7 LLC Company Overview
  • 5.29.1 TransMed7 LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.30 Vascular Nanotransfer Technologies Company Overview
  • 5.30.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview
• 5.31 Zhejiang Batai Medical Technology Co Ltd Company Overview
  • 5.31.1 Zhejiang Batai Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.32 Zylox-Tonbridge Medical Technology Co Ltd Company Overview
  • 5.32.1 Zylox-Tonbridge Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

6 PTA Peripheral DCB Catheters- Recent Developments

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer